Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Hanauer, Stephen
One or more keywords matched the following items that are connected to
Hanauer, Stephen
Item Type
Name
Concept
Placebos
Academic Article
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
Academic Article
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Academic Article
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
Academic Article
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Academic Article
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort.
Academic Article
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
Academic Article
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Academic Article
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Academic Article
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Academic Article
Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.
Academic Article
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
Academic Article
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Search Criteria
Placebos